Biofrontera AG - Company Profile
Powered by 
All the sales intelligence you need on Biofrontera AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biofrontera AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biofrontera AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biofrontera AG (Biofrontera) is a biopharmaceutical company that specialises in the research, development, and distribution of dermatological products. Biofrontera's major products include Ameluz, a topical prescription drug, and BF-RhodoLED and RhodoLED XL, proprietary red-light lamps used for photodynamic therapy of certain superficial skin cancers and their precursors. The company also markets the dermocosmetics series Belixos, which offers treatment for damaged or diseased skin. The company distributes its products through its own sales organizations in Germany, Spain, and the UK, and through independent license partners in other European countries, the US, and Asian and Oceanic markets. Biofrontera is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
Headquarters
Germany
Address
Hemmelrather Weg 201, Leverkusen, Nordrhein-Westfalen, 51377
Website
www.biofrontera.com
Telephone
49 214876320
No of Employees
76
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
B8FK (ETR)
Revenue (2024)
$23.4M
-32.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-1078.9%
(2024 vs 2023)
Market Cap*
$16.3M
Net Profit Margin (2024)
XYZ
-1,661.4%
(2024 vs 2023)
* As of and is in US$
Biofrontera AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Ameluz |
| Ameluz - Actinic Keratosis | Belixos |
| BF-RhodoLED - Actinic Keratosis | Xepi |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In June, the company sold all US assets related to Ameluz and RhodoLED to Biofrontera Inc. |
| 2024 | Contracts/Agreements | In August, the company entered into an agreement with LEO Pharma GmbH, to promote two of its established dermatological brands in Germany. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with German Medical Engineering GmbH, to promote the MultiLite daylight lamp for PDT treatment. |
Competitor Comparison
| Key Parameters | Biofrontera AG | Sun Pharmaceutical Industries Ltd | Galderma SA | Almirall Hermal GmbH | Verrica Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Germany | India | Switzerland | Germany | United States of America |
| City | Leverkusen | Mumbai | Zug | Reinbek | West Chester |
| State/Province | Nordrhein-Westfalen | Maharashtra | - | Schleswig-Holstein | Pennsylvania |
| No. of Employees | 76 | 43,000 | 10 | 299 | 71 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alexander Link | Chairman | Executive Board | 2024 | 55 |
| Pilar de la Huerta | Chief Financial Officer | Senior Management | 2022 | 56 |
| Helge Lubenow | Deputy Chairwoman | Executive Board | 2021 | 58 |
| Hansjorg Plaggemars | Director | Non Executive Board | 2024 | - |
| Heikki Lanckriet | Director | Non Executive Board | 2021 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer